Kurzfassung

An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of ENB-0040 (Enobia’s human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children < 5 Years of Age with Hypophosphatasia (HPP)